Study of 3D Radiotherapy With or Without Erlotinib (Tarceva®) in Patients With Localized Non-Small Cell Lung Cancer

Inclusion Criteria:

* Written informed consent prior to any specific procedure of the protocol.
* Histologically confirmed diagnosis of non small cell lung cancer.
* Unresectable (IA-IIIB) non-small cell lung cancer.
* Patients non susceptible for chemotherapy treatment
* Measurable disease according to RECIST criteria
* Age \> 18 years.
* ECOG performance status \< 2.
* Adequate bone marrow, hepatic, renal and respiratory function.
* Patients capable of following an adequate therapeutic compliance and accessible for a correct follow-up.
* Women at a fertile age must have a negative serum or urine pregnancy test within the 7 days prior to the beginning of the treatment.
* Patients of both genders at a fertile age, including those women having their last menstruation within the two previous years, must follow effective contraceptive measures.

Exclusion Criteria:

* Prior chemotherapy or radiotherapy.
* History of other curatively treated malignancy and no evidence of disease within the past 5 years except squamous cell skin cancer, or resected cervix carcinoma.
* Pregnant or lactating women.
* Any other severe disease or clinical conditions, as, but not only:

  1. Unstable cardiopathy despite treatment, myocardial infarction within the 6 months before entering the study
  2. Uncontrolled active infection
  3. Uncontrolled peptic ulcer, unstable diabetes mellitus or any other contraindication for treatment with corticosteroids.
  4. Autoimmune diseases.
* Concomitant treatment with any other antineoplastic therapy.
* Prior experimental pharmacological agent within the 3 weeks prior to the inclusion of the study.
* Prior treatment with EGFR targeted therapies.
* Erlotinib known hypersensibility.
* Any radiotherapy treatment contraindication.
* History of significant neurological or psychiatric disorders, including epileptic seizures.
* Any significant ophthalmologic impairment of the eye surface (Use of contact lenses is not recommended)
* Inability to take oral medication and surgical procedures affecting the absorption or implying intravenous or parenteral feeding.
* Any other underlying severe process affecting the ability to take part in the study.